|Day Low/High||32.11 / 32.29|
|52 Wk Low/High||29.83 / 37.39|
Merck & Co may face financial penalties from U.K. regulators after the Competition & Markets Authority released provisional findings of a drug pricing investigation into the American drugmaker.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.
Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 mechanisms of action, at the 53 rd Annual Meeting of the...
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, June 9, 2017 at 11:00 a.
TheStreet's Jim Cramer weighs in on Home Depot, TJX Companies, Ford, Apple, Pfizer, Nike, Target and Alibaba.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said earnings matter more than a Citigroup note saying that Pfizer may buy Allergan.
TheStreet's Jim Cramer said Berkshire Hathaway CEO Warren Buffett views Apple as a consumer products company,
Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.
While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?
Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies
Allergan shares had risen $2.55, or 1.05%, in premarket trading to $244.50.
Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday
The company has overcome some of the recent bearish expectations.
Pfizer CEO Ian Read last week was forced to field questions about M&A and there's a good chance Allergan won't be any different.
Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.
Selling premium on big names vs. buying premium has been the superior strategy this earnings season.
Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children's Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer's all-in-one...
The week's action suggests other dealmakers may be thinking the same thing as Pfizer CEO Ian Read.
Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tof Acitinib in ulcerati VE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine...
Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) for...
Two question markets hover over Wall Street on Tuesday, leading to jittery trading through the day's session.
Stocks are narrowly mixed Tuesday afternoon in the wait for earnings from world's largest company Apple.